Skip to search boxSkip to navigationSkip to main content

Health-Related Quality of Life and Satisfaction With Health Care: Relation to Clinical Stage in Mexican Patients With Multiple Myeloma

  • Luz Ma Adriana Balderas-Peña
    ,
  • Claudia Miranda-Ruvalcaba
    ,
  • Andrea Isabel Robles-Espinoza
    ,
  • Daniel Sat-Muñoz
    ,
  • Miguel Garcés Ruiz
    ,
*Corresponding author for this work
  • Hospital de Especialidades
    ,
  • Universidad de Guadalajara
    ,
  • Instituto Mexicano del Seguro Social
    ,
  • ,
  • Hospital General de Occidente
    ,
  • Universidad Autonoma de Guadalajara
Research Output:
Contribution to journal
Article
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Publication metrics

Metrics

SciVal
FWCI
0.07
SciVal
Author count
8
SciVal
Citations
5
SciVal
Paper percentile
26
Scopus
Citations

Abstract

Multiple myeloma (MM) is characterized by bone pain, pathologic fractures, bone destruction, and secondary hypercalcemia, all these conditions impact on health-related quality of life of patients. The objective was to evaluate the global health state and health-related quality of life in a group of patients with MM who attended a tertiary health-care center of the Instituto Mexicano del Seguro Social in Mexico, through the questionnaires designed by European Organization for Research and Treatment of Cancer (EORTC) quality of life group. Exploratory cross-sectional study in patients with MM treated in a Department of Hematology in a High-Specialty Medical Unit was conducted. Patients older than 18 years of age, men and women, were selected, and their informed written consent was obtained. We included all consecutive cases treated from January 2012 to December 2014. Questionnaires EORTC QLQ-C30, EORTC QLQ-MY20, and EORTC IN-PATSAT-32 were used. We studied 37 patients, 19 (51%) men and 18 women. The mean age was 61.9 years. Twenty-two (59.46%) patients presented with clinical stage III. The mean time for diagnosis was 33.11 months. The most used first-line treatment schedule was melphalan/prednisone/thalidomide (15; 40%). The global health median was 66.67, and symptoms showed a median score of 22.22. Treatment side effects score was 16.67; for general satisfaction, the median score was 75. In conclusion, the patients showed an advanced clinical stage and poor prognosis but had scores higher than 50 in functional scales and lower than 50 for symptom scales. The scores for symptom scales were related to age, renal failure, and disease-free survival. Identification of quality of life and satisfaction of care markers allow for early therapeutic intervention and efficiency and enable a change in quality of life and perception of care in Health Services.

Publication Information

Output type

Research Output:
Contribution to journal
Article
Peer-review

Original language

English

Pages from-to (Number of pages)

Pages 1073274819831281 (8 pages)

Journal (Volume, Issue Number)

Cancer Control (Volume 26, Issue 1)

Publication milestones

  • Published - 01/01/2019

Publication status

Published - 01/01/2019

ISSN

1073-2748

Publication IDs

  • Scopus: 85061971709
  • PubMed: 30786721

Funding Details

The objective of this work was to evaluate the global health state and HRQoL in a group of patients with MM,29,30 attended in a tertiary health-care center of the Instituto Mexicano del Seguro Social (IMSS) in Mexico, through the questionnaires designed by European Organization for Research and Treatment of Cancer (EORTC) quality-of-life group. The project was evaluated by the Comité Local de Investi-gación y Ética en Investigación en Salud 1301 from the Hospital de Especialidades Centro Médico Nacional de Occidente, with the approval number R-2015-1301-24. Data of each patient were managed confidentially and anonymously; data were analyzed and identified by the social security number. Patients signed the institutional informed consent form.